liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
VEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden; Tianjin Medical University, Peoples R China.
Karolinska Institute, Sweden; Zhejiang Chinese Medical University, Peoples R China.
Show others and affiliations
2014 (English)In: Cell reports, ISSN 2211-1247, E-ISSN 2211-1247, Vol. 9, no 2, 569-580 p.Article in journal (Refereed) Published
Abstract [en]

Molecular mechanisms underlying tumor VEGF-induced host anemia and bone marrow cell (BMC) mobilization remain unknown. Here, we report that tumor VEGF markedly induced sinusoidal vasculature dilation in bone marrow (BM) and BMC mobilization to tumors and peripheral tissues in mouse and human tumor models. Unexpectedly, anti-VEGFR2, but not anti-VEGFR1, treatment completely blocked VEGF-induced anemia and BMC mobilization. Genetic deletion of Vegfr2 in endothelial cells markedly ablated VEGF-stimulated BMC mobilization. Conversely, deletion of the tyrosine kinase domain from Vegfr1 gene (Vegfr1(TK-/-)) did not affect VEGF-induced BMC mobilization. Analysis of VEGFR1(+)/VEGFR2(+) populations in peripheral blood and BM showed no significant ratio difference between VEGF-and control tumor-bearing animals. These findings demonstrate that vascular dilation through the VEGFR2 signaling is the mechanism underlying VEGF-induced BM mobilization and anemia. Thus, our data provide mechanistic insights on VEGF-induced BMC mobilization in tumors and have therapeutic implications by targeting VEGFR2 for cancer therapy.

Place, publisher, year, edition, pages
Elsevier (Cell Press): OAJ / Elsevier , 2014. Vol. 9, no 2, 569-580 p.
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-112832DOI: 10.1016/j.celrep.2014.09.003ISI: 000344469100017PubMedID: 25310988OAI: oai:DiVA.org:liu-112832DiVA: diva2:776821
Note

Funding Agencies|Swedish Research Council; Swedish Cancer Foundation; Karolinska Institute Foundation; Karolinska Institute distinguished professor award; Torsten Soderbergs Foundation; Novo Nordisk Foundation; European Research Council advanced grant ANGIOFAT [250021]

Available from: 2015-01-08 Created: 2014-12-17 Last updated: 2017-12-05

Open Access in DiVA

fulltext(5667 kB)186 downloads
File information
File name FULLTEXT01.pdfFile size 5667 kBChecksum SHA-512
675321420930f86a0d13084307560106a8c926aa27a19d2b33f0233bcb0f215c0c88fffa138fcaa8825c8aff7f6a76533f0e6150caa87bcf965fd831a9d2188f
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Cao, Yihai

Search in DiVA

By author/editor
Cao, Yihai
By organisation
Division of Cardiovascular MedicineFaculty of Health Sciences
In the same journal
Cell reports
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 186 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 73 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf